Omeros Over-Promises and Under-Delivers
Two stocks in the biotech/healthcare space were pummeled today after receiving negative news. First up is Omeros (OMER), which disseminated a misleading press release stating that they had additional “positive” data on their study of OMS721. However, those positive points were greatly outweighed by the fact that the study showed very little effect for the […]
Read Article